Tolga Tanguler serves as the Executive Vice President and Chief Commercial Officer at Alnylam Pharmaceuticals Inc., a leading biotechnology company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. With a robust background in pharmaceuticals and healthcare, Tanguler has played a pivotal role in steering Alnylam's commercial strategy, ensuring the successful launch and market penetration of its innovative therapies. Before joining Alnylam, Tanguler held several senior leadership positions in the pharmaceutical industry. He was instrumental in driving growth and expanding market presence for companies such as Merck & Co., where he served as Vice President and General Manager for various regions. His strategic vision and deep understanding of global markets have been crucial in navigating the complex landscape of pharmaceutical commercialization. At Alnylam, Tanguler oversees the global commercial operations, spearheading efforts to bring life-changing RNAi therapies to patients worldwide. His leadership has been vital in the successful launch of multiple products, including Onpattro and Givlaari, which have significantly impacted the treatment landscape for rare diseases. Tanguler's achievements extend beyond his corporate roles; he is also recognized for his contributions to the broader healthcare community. He has been an advocate for patient access to innovative treatments and has worked closely with various stakeholders to address healthcare disparities. His commitment to excellence and innovation continues to drive Alnylam's mission to transform the lives of people affected by rare and serious diseases.